Oric Pharmaceuticals, Inc.
ORIC Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$8.96
KIRA · Stoqly’s AI analyst, in plain words
- Oric Pharmaceuticals, Inc. lost $129M in fiscal 2025.
- Free cash flow was −$112M in fiscal 2025, — of revenue.
Market cap
$967M
P/E
—
Revenue
—
Net income
−$129M
Free cash flow
−$112M
Operating margin
—
Oric Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$129M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Oric Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- Oric Pharmaceuticals, Inc.
- CIK
- 0001796280
Oric Pharmaceuticals, Inc. · ORIC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$78.7M | −$89.1M | −$101M | −$128M | −$129M |
| Diluted EPS | −$2.07 | −$2.25 | −$1.96 | −$1.83 | −$1.47 |
| Cash | |||||
| Cash from operations | −$59.5M | −$75.1M | −$85.7M | −$113M | −$111M |
| Capital expenditure | $0.9M | $2.1M | $0.8M | $1.2M | $0.7M |
| Free cash flow | −$60.5M | −$77.2M | −$86.5M | −$114M | −$112M |
| Share count change | 73.0% | 4.5% | 29.7% | 35.5% | 25.9% |
| Debt and strength | |||||
| Cash and short-term investments | $237M | $206M | $208M | $256M | $281M |
| Debt incl. finance leases | $10.5M | — | — | — | — |
| Shareholders' equity | $273M | $222M | $224M | $243M | $384M |
| Current ratio | 15.9x | 13.7x | 10.4x | 10.6x | 14.1x |
| Returns and quality | |||||
| Return on capital | −134.0% | — | — | — | — |
| Return on equity | −28.0% | −36.0% | −45.1% | −54.7% | −41.3% |
| Return on tangible equity | −28.8% | −40.1% | −44.9% | −52.6% | −33.7% |
| Piotroski F-score | 1 | — | — | — | — |
| Altman Z'' | 11.7 | 7.7 | 4.8 | 3.7 | 12.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.0M
4 insiders
Of sales under plans
83%
$2.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Oric Pharmaceuticals, Inc. · ORIC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.96 a share, the company is worth $967M.
Source: SEC EDGAR XBRL filings (CIK 0001796280). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.